Onychomycosis Treatment Guidelines

Introduction to Onychomycosis Treatment

The American College of Dermatology recommends oral terbinafine 250 mg once daily as the first-line treatment for dermatophyte onychomycosis, with a treatment duration of 6 weeks for fingernails and 12 weeks for toenails 1
Mycological confirmation is mandatory before initiating any antifungal therapy to confirm the causative organism 1

Terbinafine 250 mg once daily for 6 weeks for fingernails and 12 weeks for toenails is the standard first-line treatment, with a complete cure rate of 55% versus 26% for itraconazole at 72 weeks 1, 3
Terbinafine demonstrates superior efficacy and fungicidal activity against dermatophytes, with minimal drug-drug interactions compared to azole antifungals 1
Baseline liver function tests and complete blood count are required before initiating terbinafine therapy 2

Itraconazole is the second-line alternative, with two dosing options: pulse therapy (400 mg daily for 1 week per month) or continuous therapy (200 mg daily for 12 weeks) 1, 2
Itraconazole has significant interactions with statins and is contraindicated in heart failure due to negative inotropic effects 1, 2, 3
Fluconazole 150-450 mg once weekly for at least 6 months is an alternative option for toenail infections, with fewer drug interactions with statins than itraconazole 2

Topical therapy is appropriate for mild, superficial, or distal onychomycosis involving less than 50% of the nail plate without matrix involvement 1
FDA-approved topical agents include efinaconazole 10% solution, tavaborole 5% solution, and ciclopirox 8% lacquer, with varying mycological cure rates and application durations 1, 2, 4
Tavaborole is particularly useful in patients with renal impairment or hepatic impairment, with minimal systemic absorption and no hepatic contraindications 4

Terbinafine is the oral antifungal agent of choice in diabetic patients, due to low risk of drug interactions and hypoglycemia 3
Itraconazole should be avoided in diabetic patients due to increased prevalence of cardiac disease and contraindication in heart failure 3
Terbinafine and fluconazole are preferred in immunosuppressed patients, due to increased risk of interaction between itraconazole/ketoconazole and antiretrovirals 3

Monthly removal of unattached, infected nail by a healthcare professional is recommended, along with weekly trimming and filing away loose nail material by the patient 3
Decontamination or replacement of contaminated footwear is essential to eliminate fungal reservoirs, along with application of antifungal powders and periodic spraying of terbinafine solution into shoes 2

Patients should be re-evaluated 3-6 months after treatment initiation, with assessment including both clinical improvement and mycological cure (negative microscopy and culture) 1
A follow-up period of at least 48 weeks from the start of treatment is ideal to identify potential relapse, with up to 18 months required for toenail plate to grow out fully 2, 3

In cases of first treatment failure, terbinafine 250 mg daily should be resumed for another 6 weeks for fingernails or 12 weeks for toenails, after confirming the infection is due to dermatophytes and repeating pre-treatment checks 1
In cases of second treatment failure, itraconazole should be used as a second-line alternative, with a dose of 200 mg daily for 12 weeks or 400 mg daily for 1 week per month for 2-3 pulses 1